CA2069439A1 - Anticorps monoclonaux, leur production et leur utilisation - Google Patents

Anticorps monoclonaux, leur production et leur utilisation

Info

Publication number
CA2069439A1
CA2069439A1 CA002069439A CA2069439A CA2069439A1 CA 2069439 A1 CA2069439 A1 CA 2069439A1 CA 002069439 A CA002069439 A CA 002069439A CA 2069439 A CA2069439 A CA 2069439A CA 2069439 A1 CA2069439 A1 CA 2069439A1
Authority
CA
Canada
Prior art keywords
antibody
prodrug
cancer
human
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002069439A
Other languages
English (en)
Inventor
Susumu Iwasa
Kayoko Okamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2069439A1 publication Critical patent/CA2069439A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002069439A 1989-12-15 1990-12-14 Anticorps monoclonaux, leur production et leur utilisation Abandoned CA2069439A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP32654589 1989-12-15
JP1-326545 1989-12-15
JP9732390 1990-04-11
JP2-97323 1990-04-11
JP30160890 1990-11-06
JP2-301608 1990-11-06
PCT/JP1990/001631 WO1991009134A1 (fr) 1989-12-15 1990-12-14 Anticorps biospecifique des cellules cancereuses et enzyme presentant des caracteristiques d'activation promedicamenteuse

Publications (1)

Publication Number Publication Date
CA2069439A1 true CA2069439A1 (fr) 1991-06-16

Family

ID=27308381

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002069439A Abandoned CA2069439A1 (fr) 1989-12-15 1990-12-14 Anticorps monoclonaux, leur production et leur utilisation

Country Status (3)

Country Link
EP (1) EP0505566A1 (fr)
CA (1) CA2069439A1 (fr)
WO (1) WO1991009134A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2108451A1 (fr) * 1991-04-26 1992-10-27 Beverley J. Randle Nouveaux anticorps et methodes d'utilisation
US6787153B1 (en) 1991-06-28 2004-09-07 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
CA2072249C (fr) * 1991-06-28 2003-06-17 Saiko Hosokawa Anticorps monoclonal humain liant specifiquement a la surface d'un antigene des membranes des cellules cancereuses
EP0611306B1 (fr) * 1991-11-08 1998-07-08 Somatogen, Inc. Hemoglobines utilisees comme agents administrateurs de medicaments
GB9200415D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
GB9200417D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
GB9819411D0 (en) * 1998-09-04 1998-10-28 Ks Biomedix Ltd Antibodies
ATE499115T1 (de) * 1998-09-18 2011-03-15 Immunomedics Inc Antikörper verwiesene enzymprodrugtherapie mit glukuronidase
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US6573074B2 (en) 2000-04-12 2003-06-03 Smithkline Beecham Plc Methods for ansamitocin production
US7445802B2 (en) 2000-12-26 2008-11-04 Yeda Research And Development Co. Ltd Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
WO2010019257A2 (fr) 2008-08-13 2010-02-18 The Johns Hopkins University Activation de promédicament dans des cellules cancéreuses à l'aide de commutateurs moléculaires
WO2014028668A2 (fr) * 2012-08-14 2014-02-20 Minerva Biotechnologies Corporation Composés thérapeutiques activant les cellules souches
CN116199790A (zh) 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
CN106554375B (zh) * 2016-06-08 2019-10-18 浙江海正药业股份有限公司 一种蒽环类化合物、其制备方法及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0142905A2 (fr) * 1983-03-30 1985-05-29 Bio-Response Inc. Substance thérapeutique pour le traitement de maladies telles que le cancer
WO1986001720A1 (fr) * 1984-09-13 1986-03-27 Cytogen Corporation Conjugues d'agents therapeutiques-anticorps
GB8528761D0 (en) * 1985-11-22 1985-12-24 Axon Healthcare Ltd Enzyme-coupled antibodies
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems

Also Published As

Publication number Publication date
EP0505566A1 (fr) 1992-09-30
WO1991009134A1 (fr) 1991-06-27

Similar Documents

Publication Publication Date Title
US5141736A (en) Bispecific monoclonal antibody, its production and use
CA2069439A1 (fr) Anticorps monoclonaux, leur production et leur utilisation
US5591593A (en) Minimum recognition unit of a PEM mucin tandem repeat specific monoclonal antibody and detection method using same
US5028697A (en) Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
JP4255512B2 (ja) 多剤耐性表現型を標的とするための多重特異性免疫複合体と抗体組成物
AU597903B2 (en) Antibody complexes of hapten-modified diagnostic or therapeutic agents
EP0578774B1 (fr) Anticorps monoclonaux de recepteurs de facteurs de cellules souches
US5217713A (en) Cytotoxic bispecific monoclonal antibody, its production and use
US7144704B2 (en) Methods and reagents for preparing and using immunological agents specific for P-glycoprotein
JPH03502885A (ja) 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
WO2024012566A9 (fr) Anticorps, lieurs, charge utile, conjugués et leurs applications
JP2002509158A (ja) アーム付きリガンドの送達向上のための抗体と受容体ターゲティング部分
EP1354896B1 (fr) Anticorps monoclonal dirigé contre l'antigène humain bst2
EP4442828A1 (fr) Anticorps masqués clivables par protéase
US5144012A (en) Cytotoxic drug conjugates
WO2024213091A9 (fr) Combinaison d'un conjugué anticorps-médicament et d'un anticorps anti-pd-1, et son utilisation
AU2004289821B2 (en) Adenocarcinoma specific antibody SAM-6, and uses thereof
EP0336405B1 (fr) Complexes protéiniques contre le cancer humain, leur préparation et leur utilisation
IWASA et al. Selective cytotoxicity of drug-monoclonal antibody conjugates against murine bladder tumor cells
JPH05506563A (ja) モノクローナル抗体、その製造法及び用途
AU611087B2 (en) Cytorhodin S derivatives, a process for their preparation and their use as medicaments
JPH04187096A (ja) 二重特異性を有するハイブリッド・モノクローナル抗体
JPH0347090A (ja) 二重特異性を有するハイブリッドモノクローナル抗体
HK40110970A (en) Protease-cleavable masked antibodies
JP2024501739A (ja) ヒトｌｉｆｒ抗原結合タンパク質、その製造方法及び応用

Legal Events

Date Code Title Description
FZDE Discontinued